Patents by Inventor H. Bryan Brewer
H. Bryan Brewer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180355021Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: June 8, 2018Publication date: December 13, 2018Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20170174747Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: March 9, 2017Publication date: June 22, 2017Inventors: MARC BELLOTTI, H. BRYAN BREWER, HASSIBULLAH AKEEFE, ADAM PAUL CONNER, TIMOTHY JON PERLMAN
-
Publication number: 20160324925Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: July 20, 2016Publication date: November 10, 2016Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Patent number: 8835378Abstract: Disclosed herein are peptides or peptide analogs with multiple amphipathic ?-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic ?-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.Type: GrantFiled: February 28, 2012Date of Patent: September 16, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Alan T. Remaley, Stephen J. Demosky, John A. Stonik, Marcelo J. A. Amar, Edward B. Neufeld, H. Bryan Brewer, Fairwell Thomas
-
Publication number: 20140107029Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: December 19, 2013Publication date: April 17, 2014Applicant: HDL TherapeuticsInventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Patent number: 8637460Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: GrantFiled: August 31, 2012Date of Patent: January 28, 2014Assignee: HDL Therapeutics LLCInventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20130052167Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: August 31, 2012Publication date: February 28, 2013Applicant: HDL TherapeuticsInventors: Marc BELLOTTI, H. Bryan BREWER, JR., Hassibullah AKEEFE, Adam Paul CONNER, Timothy Jon PERLMAN
-
Patent number: 8268787Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: GrantFiled: August 31, 2011Date of Patent: September 18, 2012Assignee: HDL TherapeuticsInventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20120148642Abstract: Disclosed herein are peptides or peptide analogs with multiple amphipathic ?-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic ?-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.Type: ApplicationFiled: February 28, 2012Publication date: June 14, 2012Applicants: Health and Human ServicesInventors: Alan T. Remaley, Stephen J. Demosky, John A. Stonik, Marcelo J.A. Amar, Edward B. Neufeld, H. Bryan Brewer, Fairwell Thomas
-
Patent number: 8148323Abstract: Disclosed herein are peptides or peptide analogs with multiple amphipathic ?-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic ?-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.Type: GrantFiled: April 23, 2010Date of Patent: April 3, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Alan T. Remaley, Stephen J. Demosky, John A. Stonik, Marcelo J. A. Amar, Edward B. Neufeld, H. Bryan Brewer, Fairwell Thomas
-
Publication number: 20110318423Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: August 31, 2011Publication date: December 29, 2011Applicant: HDL THERAPEUTICSInventors: Marc Bellotti, H. Bryan Brewer, JR., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Patent number: 8048015Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: GrantFiled: March 24, 2008Date of Patent: November 1, 2011Assignee: HDL TherapeuticsInventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Patent number: 8030281Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: GrantFiled: March 5, 2008Date of Patent: October 4, 2011Assignee: HDL TherapeuticsInventors: Marc Bellotti, H. Bryan Brewer, Jr., Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20100203099Abstract: Disclosed herein are peptides or peptide analogs with multiple amphipathic ?-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic ?-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.Type: ApplicationFiled: April 23, 2010Publication date: August 12, 2010Inventors: ALAN T. REMALEY, STEPHEN J. DEMOSKY, JOHN A. STONIK, MARCELE J.A. AMAR, EDWARD B. NEUFELD, H. BRYAN BREWER, FAIRWELL THOMAS
-
Patent number: 7572771Abstract: Disclosed herein are peptides or peptide analogs with multiple amphipathic ?-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic ?-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.Type: GrantFiled: October 14, 2005Date of Patent: August 11, 2009Assignee: The United States of America as represented by the Departments of Health and Human ServicesInventors: Alan T. Remaley, Stephen J. Demosky, John A. Stonik, Marcele J. A. Amar, Edward B. Neufeld, H. Bryan Brewer, Fairwell Thomas
-
Patent number: 7479480Abstract: Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided herein are methods of using the peptides to treat or inhibit diseases including dyslipidemic disorders, stroke and myocardial infarction. Also provided are methods of detecting plaque in vessels using the labeled peptides of the present invention.Type: GrantFiled: May 15, 2008Date of Patent: January 20, 2009Assignee: Lipid Sciences, Inc.Inventor: H. Bryan Brewer, Jr.
-
Publication number: 20080255051Abstract: Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided herein are methods of using the peptides to treat or inhibit diseases including dyslipidemic disorders, stroke and myocardial infarction. Also provided are methods of detecting plaque in vessels using the labeled peptides of the present invention.Type: ApplicationFiled: May 15, 2008Publication date: October 16, 2008Applicant: Lipid Sciences, Inc.Inventor: H. Bryan Brewer, Jr.
-
Publication number: 20080230465Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: March 24, 2008Publication date: September 25, 2008Applicant: Lipid Sciences, Inc.Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20080234621Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: March 24, 2008Publication date: September 25, 2008Applicant: Lipid Sciences, Inc.Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman
-
Publication number: 20080227726Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: March 5, 2008Publication date: September 18, 2008Inventors: Marc Bellotti, H. Bryan Brewer, Hassibullah Akeefe, Adam Paul Conner, Timothy Jon Perlman